Kunqi Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kunqi Su has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Chunfeng Zhang
Department of Medical Genetics, School of Basic Medical Sciences, Peking University, Beijing, China
4 shared publications- Xiaojuan Du
Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing, China
4 shared publications Chang Wang
Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing, China
3 shared publicationsShiqi Sun
Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing, China
3 shared publicationsXiaofeng Liu
Hepatopancreatobiliary Surgery Department I, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China
3 shared publications- Bao-Cai Xing
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Hepatopancreatobiliary Surgery Department I, Peking University Cancer Hospital and Institute, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 7 November 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-17
Pre-rRNAs control mitosis by maintaining chromosomal segregation through protecting SMC2 from AURKA-mediated phosphorylation
In interphase, 47S pre-rRNA is transcribed by RNA polymerase I (Pol I) and processed to form intermediate pre-rRNAs and finally produce mature rRNAs in the nucleolus. During mitosis, nucleolus disassembles and pre-rRNAs including 45S, 30S and 32S pre-rRNAs relocate in the peri-chromosomal region (PR). Inhibition of pre-rRNA transcription impairs chromosome dispersion in prometaphase. However, how pre-rRNAs regulate mitosis remains elusive. Here, we unravel a novel mechanism for pre-rRNAs to control mitosis. Inhibition of Pol I prolongs the mitotic process and induces defective chromosomal segregation, resulting in mitotic catastrophe. We isolated chromosome and determined the chromosome-binding proteins by mass-spectrometry. Using quantitative proteomics analysis, immunoprecipitation and immunofluorescent staining, we found that AURKA approaches chromosome when Pol I is inhibited. The AURKA-binding proteins on the chromosome were determined by immunoprecipitation and mass-spectrometry after cells were treated with Act D, BMH-21 or CX5461, respectively, and the chromosomal segregation controlling proteins were selected. When Pol I was inhibited, the binding of AURKA with SMC2, the crucial component of Condensin, is significantly enhanced. Importantly, SMC2 is phosphorylated by AURKA only when Pol I was inhibited. Alignment of SMC2 amino acid sequence with substrates of AURKA shows that SMC2 possesses the consensus R/K/N-R-X-S/T-B, and T574 is the only potential AURKA-catalyzed phosphorylation site. Indeed, SMC2 T574 is phosphorylated by AURKA in cell and in vitro. Thereafter, we generated SMC2 T574-P specific antibody, and confirmed that endogenous SMC2 T574 is phosphorylated by AURKA in mitosis in the absence of pre-rRNAs. Consequently, phosphorylation of SMC2 T574 disrupts the SMC2/SMC4 binding and the binding of SMC2 and SMC4 to chromosomal DNA, leading to chromosomal segregation defect. The phosphorylation deficient Flag-SMC2 T574A reverses the mitotic catastrophe caused by Pol I inhibition. Collectively, we demonstrate that pre-rRNAs protect SMC2 from the AURKA-mediated phosphorylation to maintain normal mitosis.
- 7 November 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-17
Open AccessPre-rRNAs control mitosis by maintaining chromosomal segregation through protecting SMC2 from AURKA-mediated phosphorylation
In interphase, 47S pre-rRNA is transcribed by RNA polymerase I (Pol I) and processed to form intermediate pre-rRNAs and finally produce mature rRNAs in the nucleolus. During mitosis, nucleolus disassembles and pre-rRNAs including 45S, 30S and 32S pre-rRNAs relocate in the peri-chromosomal region (PR). Inhibition of pre-rRNA transcription impairs chromosome dispersion in prometaphase. However, how pre-rRNAs regulate mitosis remains elusive. Here, we unravel a novel mechanism for pre-rRNAs to control mitosis. Inhibition of Pol I prolongs the mitotic process and induces defective chromosomal segregation, resulting in mitotic catastrophe. We isolated chromosome and determined the chromosome-binding proteins by mass-spectrometry. Using quantitative proteomics analysis, immunoprecipitation and immunofluorescent staining, we found that AURKA approaches chromosome when Pol I is inhibited. The AURKA-binding proteins on the chromosome were determined by immunoprecipitation and mass-spectrometry after cells were treated with Act D, BMH-21 or CX5461, respectively, and the chromosomal segregation controlling proteins were selected. When Pol I was inhibited, the binding of AURKA with SMC2, the crucial component of Condensin, is significantly enhanced. Importantly, SMC2 is phosphorylated by AURKA only when Pol I was inhibited. Alignment of SMC2 amino acid sequence with substrates of AURKA shows that SMC2 possesses the consensus R/K/N-R-X-S/T-B, and T574 is the only potential AURKA-catalyzed phosphorylation site. Indeed, SMC2 T574 is phosphorylated by AURKA in cell and in vitro. Thereafter, we generated SMC2 T574-P specific antibody, and confirmed that endogenous SMC2 T574 is phosphorylated by AURKA in mitosis in the absence of pre-rRNAs. Consequently, phosphorylation of SMC2 T574 disrupts the SMC2/SMC4 binding and the binding of SMC2 and SMC4 to chromosomal DNA, leading to chromosomal segregation defect. The phosphorylation deficient Flag-SMC2 T574A reverses the mitotic catastrophe caused by Pol I inhibition. Collectively, we demonstrate that pre-rRNAs protect SMC2 from the AURKA-mediated phosphorylation to maintain normal mitosis.
- Open Access
- 31 July 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (7) , 1-17
Chemotherapy-induced acetylation of ACLY by NAT10 promotes its nuclear accumulation and acetyl-CoA production to drive chemoresistance in hepatocellular carcinoma
Chemotherapeutic efficacy is seriously impeded by chemoresistance in more than half of hepatocellular carcinoma (HCC) patients. However, the mechanisms involved in chemotherapy-induced upregulation of chemoresistant genes are not fully understood. Here, this study unravels a novel mechanism controlling nuclear acetyl-CoA production to activate the transcription of chemoresistant genes in HCC. NAT10 is upregulated in HCC tissues and its upregulation is correlated with poor prognosis of HCC patients. NAT10 is also upregulated in chemoresistant HCC cells. Targeting NAT10 increases the cytotoxicity of chemotherapy in HCC cells and mouse xenografts. Upon chemotherapy, NAT10 translocates from the nucleolus to the nucleus to activate the transcription of CYP2C9 and PIK3R1. Additionally, nuclear acetyl-CoA is specifically upregulated by NAT10. Mechanistically, NAT10 binds with ACLY in the nucleus and acetylates ACLY at K468 to counteract the SQSTM1-mediated degradation upon chemotherapy. ACLY K468-Ac specifically accumulates in the nucleus and increases nuclear acetyl-CoA production to activate the transcription of CYP2C9 and PIK3R1 through enhancing H3K27ac. Importantly, K468 is required for nuclear localization of ACLY. Significantly, ACLY K468-Ac is upregulated in HCC tissues, and ablation of ACLY K468-Ac sensitizes HCC cells and mouse xenografts to chemotherapy. Collectively, these findings identify NAT10 as a novel chemoresistant driver and the blockage of NAT10-mediated ACLY K468-Ac possesses the potential to attenuate HCC chemoresistance.
- 31 July 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (7) , 1-17
Open AccessChemotherapy-induced acetylation of ACLY by NAT10 promotes its nuclear accumulation and acetyl-CoA production to drive chemoresistance in hepatocellular carcinoma
Chemotherapeutic efficacy is seriously impeded by chemoresistance in more than half of hepatocellular carcinoma (HCC) patients. However, the mechanisms involved in chemotherapy-induced upregulation of chemoresistant genes are not fully understood. Here, this study unravels a novel mechanism controlling nuclear acetyl-CoA production to activate the transcription of chemoresistant genes in HCC. NAT10 is upregulated in HCC tissues and its upregulation is correlated with poor prognosis of HCC patients. NAT10 is also upregulated in chemoresistant HCC cells. Targeting NAT10 increases the cytotoxicity of chemotherapy in HCC cells and mouse xenografts. Upon chemotherapy, NAT10 translocates from the nucleolus to the nucleus to activate the transcription of CYP2C9 and PIK3R1. Additionally, nuclear acetyl-CoA is specifically upregulated by NAT10. Mechanistically, NAT10 binds with ACLY in the nucleus and acetylates ACLY at K468 to counteract the SQSTM1-mediated degradation upon chemotherapy. ACLY K468-Ac specifically accumulates in the nucleus and increases nuclear acetyl-CoA production to activate the transcription of CYP2C9 and PIK3R1 through enhancing H3K27ac. Importantly, K468 is required for nuclear localization of ACLY. Significantly, ACLY K468-Ac is upregulated in HCC tissues, and ablation of ACLY K468-Ac sensitizes HCC cells and mouse xenografts to chemotherapy. Collectively, these findings identify NAT10 as a novel chemoresistant driver and the blockage of NAT10-mediated ACLY K468-Ac possesses the potential to attenuate HCC chemoresistance.
- Open Access
- 17 May 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (5) , 1-15
U3 snoRNA inter-regulates with DDX21 in the perichromosomal region to control mitosis
U3 snoRNA is essential for ribosome biogenesis during interphase. Upon mitotic onset, the nucleolus disassembles and U3 snoRNA relocates to the perichromosomal region (PR) to be considered as a chromosome passenger. Whether U3 controls mitosis remains unknown. Here, we demonstrate that U3 snoRNA is required for mitotic progression. We identified DDX21 as the predominant U3-binding protein during mitosis and confirmed that U3 snoRNA colocalizes with DDX21 in the PR. DDX21 knockdown induces mitotic catastrophe and similar mitotic defects caused by U3 snoRNA depletion. Interestingly, the uniform PR distribution of U3 snoRNA and DDX21 is interdependent. DDX21 functions in mitosis depending on its PR localization. Mechanistically, U3 snoRNA regulates DDX21 PR localization through maintaining its mobility. Moreover, Cy5-U3 snoRNA downsizes the fibrous condensates of His-DDX21 at proper molecular ratios in vitro. This work highlights the importance of the equilibrium between U3 snoRNA and DDX21 in PR formation and reveals the potential relationship between the PR assembly and mitotic regulation.
- 17 May 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (5) , 1-15
Open AccessU3 snoRNA inter-regulates with DDX21 in the perichromosomal region to control mitosis
U3 snoRNA is essential for ribosome biogenesis during interphase. Upon mitotic onset, the nucleolus disassembles and U3 snoRNA relocates to the perichromosomal region (PR) to be considered as a chromosome passenger. Whether U3 controls mitosis remains unknown. Here, we demonstrate that U3 snoRNA is required for mitotic progression. We identified DDX21 as the predominant U3-binding protein during mitosis and confirmed that U3 snoRNA colocalizes with DDX21 in the PR. DDX21 knockdown induces mitotic catastrophe and similar mitotic defects caused by U3 snoRNA depletion. Interestingly, the uniform PR distribution of U3 snoRNA and DDX21 is interdependent. DDX21 functions in mitosis depending on its PR localization. Mechanistically, U3 snoRNA regulates DDX21 PR localization through maintaining its mobility. Moreover, Cy5-U3 snoRNA downsizes the fibrous condensates of His-DDX21 at proper molecular ratios in vitro. This work highlights the importance of the equilibrium between U3 snoRNA and DDX21 in PR formation and reveals the potential relationship between the PR assembly and mitotic regulation.
- 24 February 2022
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 29 (4) , 846-860
NAT10 regulates mitotic cell fate by acetylating Eg5 to control bipolar spindle assembly and chromosome segregation
Cell fate of mitotic cell is controlled by spindle assembly. Deficient spindle assembly results in mitotic catastrophe leading to cell death to maintain cellular homeostasis. Therefore, inducing mitotic catastrophe provides a strategy for tumor therapy. Nucleolar acetyltransferase NAT10 has been found to regulate various cellular processes to maintain cell homeostasis. Here we report that NAT10 regulates mitotic cell fate by acetylating Eg5. NAT10 depletion results in multinuclear giant cells, which is the hallmark of mitotic catastrophe. Live-cell imaging showed that knockdown of NAT10 dramatically prolongs the mitotic time and induces defective chromosome segregation including chromosome misalignment, bridge and lagging. NAT10 binds and co-localizes with Eg5 in the centrosome during mitosis. Depletion of NAT10 reduces the centrosome loading of Eg5 and impairs the poleward movement of centrosome, leading to monopolar and asymmetrical spindle formation. Furthermore, NAT10 stabilizes Eg5 through its acetyltransferase function. NAT10 acetylates Eg5 at K771 to control Eg5 stabilization. We generated K771-Ac specific antibody and showed that Eg5 K771-Ac specifically localizes in the centrosome during mitosis. Additionally, K771 acetylation is required for the motor function of Eg5. The hyper-acetylation mimic Flag-Eg5 K771Q but not Flag-Eg5 rescued the NAT10 depletion-induced defective spindle formation and mitotic catastrophe, demonstrating that NAT10 controls mitosis through acetylating Eg5 K771. Collectively, we identify Eg5 as an important substrate of NAT10 in the control of mitosis and provide K771 as an essential acetylation site in the stabilization and motor function of Eg5. Our findings reveal that targeting the NAT10-mediated Eg5 K771 acetylation provides a potential strategy for tumor therapy.
- 24 February 2022
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 29 (4) , 846-860
NAT10 regulates mitotic cell fate by acetylating Eg5 to control bipolar spindle assembly and chromosome segregation
Cell fate of mitotic cell is controlled by spindle assembly. Deficient spindle assembly results in mitotic catastrophe leading to cell death to maintain cellular homeostasis. Therefore, inducing mitotic catastrophe provides a strategy for tumor therapy. Nucleolar acetyltransferase NAT10 has been found to regulate various cellular processes to maintain cell homeostasis. Here we report that NAT10 regulates mitotic cell fate by acetylating Eg5. NAT10 depletion results in multinuclear giant cells, which is the hallmark of mitotic catastrophe. Live-cell imaging showed that knockdown of NAT10 dramatically prolongs the mitotic time and induces defective chromosome segregation including chromosome misalignment, bridge and lagging. NAT10 binds and co-localizes with Eg5 in the centrosome during mitosis. Depletion of NAT10 reduces the centrosome loading of Eg5 and impairs the poleward movement of centrosome, leading to monopolar and asymmetrical spindle formation. Furthermore, NAT10 stabilizes Eg5 through its acetyltransferase function. NAT10 acetylates Eg5 at K771 to control Eg5 stabilization. We generated K771-Ac specific antibody and showed that Eg5 K771-Ac specifically localizes in the centrosome during mitosis. Additionally, K771 acetylation is required for the motor function of Eg5. The hyper-acetylation mimic Flag-Eg5 K771Q but not Flag-Eg5 rescued the NAT10 depletion-induced defective spindle formation and mitotic catastrophe, demonstrating that NAT10 controls mitosis through acetylating Eg5 K771. Collectively, we identify Eg5 as an important substrate of NAT10 in the control of mitosis and provide K771 as an essential acetylation site in the stabilization and motor function of Eg5. Our findings reveal that targeting the NAT10-mediated Eg5 K771 acetylation provides a potential strategy for tumor therapy.